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Abstract
Alterations in smooth muscle cell function and phenotype contribute to tissue
remodeling in various pathologies including obstructive lung (e.g., asthma) and
vascular (e.g., atherosclerosis) diseases. The extracellular matrix (ECM) is a major
influence on the biology of smooth muscle cells, being an important support structure
that provides signaling cues through its biochemical and biophysical properties. ECM
factors activate biochemical and mechano-transduction signaling pathways, which
modulate smooth muscle cell contraction, stiffness, survival, growth, cytokine
production and migration (i.e., cellular processes which contribute to changes in tissue
architecture). The interaction of the ECM with smooth muscle cells is a dynamic multi-
directional process, as smooth muscle cells also produce ECM protein, as well as
proteases and cross-linking enzymes which regulate ECM form and structure.
Understanding the molecular basis of ECM modifications and their impact on smooth
muscle cell function in disease may lead to the development of novel therapies. This
chapter reviews interactions between the ECM and smooth muscle cell and how they
become altered in disease, using obstructive lung and vascular diseases as examples.
From a pharmacological and therapeutic perspective, strategies that alter the
phenotype of the smooth muscle cell in disease will be discussed. Emphasis will be
given to approaches that target the proteases and mediators of ECM-smooth muscle
cell signaling as potential treatments for pulmonary and vascular disease. Proteases
of the coagulation and plasminogen activation systems have been given particular
attention as they not only have a role in forming and modifying ECM, but also can
directly stimulate changes in smooth muscle cell function and phenotype via
activating receptors such as the protease-activated receptor-1 (PAR-1) and integrins.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
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1. Introduction
Smooth muscle cells function by contracting following activation of actin and myosin fila‐
ments, in a process involving myosin light chain phosphorylation, mediated by Ca2+-depend‐
ent pathways [1]. In many diseases, alterations in smooth muscle cell function including
contractile responses, growth and phenotype, contribute to tissue remodeling. In obstructive
lung diseases such as severe asthma and chronic obstructive pulmonary disease (COPD),
increases in the stiffness and mass of the airway smooth muscle (ASM) bundle contribute to
fixed airway obstruction and hyper-responsiveness [2, 3]. In vascular injury and diseases such
as atherosclerosis and pulmonary arterial hypertension (PAH), the migration, stiffening,
proliferation and growth of vascular smooth muscle (VSM) cells contribute to the enlargement
of the blood vessel wall, which in effect reduces lumen size, thus an increase in vascular
resistance [4, 5]. Alterations in the microenvironment of the smooth muscle cell, particularly
in the composition and structure of the ECM, accompany changes in smooth muscle biology
in disease. Smooth muscle cells have a large role in modifying their microenvironment in
disease by producing ECM protein (e.g., collagen, fibrin, fibronectin and proteoglycans [6])
and factors which regulate ECM formation (e.g., tissue factor in fibrin formation [7]). Further‐
more, smooth muscle cells secrete proteases (e.g., urokinase plasminogen activator or uPA [8])
and crosslinking enzymes (e.g., lysyl oxidases [9]) which modulate ECM structure and form.
The ECM in turn regulates smooth muscle function by the provision of both biochemical and
biomechanical cues, in a process involving complexes formed between integrins, focal
adhesion (FA) proteins and the actin-cytoskeleton. Both biochemical and mechano-transduc‐
tion signaling in smooth muscle cells are mutually interdependent. In disease, the altered ECM
may perpetuate tissue remodeling by augmenting smooth muscle growth, migration, cytokine
production, cell stiffness and proliferation in a detrimental feed forward mechanism. Aside
from important biomechanical contributions in tissue remodelling, smooth muscle cells are
also potent producers of an array of inflammatory mediators, including cytokines, chemokines
and cell adhesion molecules (CAMs) [10-13]. These inflammatory mediators, as well as the
ECM produced by smooth muscle cells, influence the type and quantity of inflammatory cells
that infiltrate damaged tissue in disease [14, 15].
2. Smooth muscle cells
Smooth muscle cells are phenotypically-plastic stromal cells, which are very capable of
differentiating in response to injury and inflammation in disease. Whilst myogenic, the
structure, mechanical properties, contractility and function of smooth muscle cells are different
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to those of striated and cardiac muscle cells. The involuntary non-striated smooth muscle cells
are found in many tissues and organs including the gastro-intestinal tract, the respiratory
system, reproductive tract, urinary bladder, skin, iris of the eyes, kidneys and blood vessels.
Smooth muscle cells contract and relax to regulate the luminal diameter and viscoelasticity of
conducting vessels (e.g., the vasculature and bronchioles) [16] and sphincters (e.g., the urethral
and pre-capillary sphincters) [17]. Smooth muscle contraction also has a role in the rhythmic
peristalsis of tissues and organs of the gastro-intestinal tract and respiratory systems [18].
Whilst the structure and function of smooth muscle cells in different tissues are quite similar,
they can contrast in their mode of activation, whether that be spontaneous involving ionic
channel dynamics or by physiochemical agents (e.g., hormones and neurotransmitters) or
external agents (e.g., CO2). The actin-myosin contractile apparatus mediates the force genera‐
tion responsible for smooth muscle contraction, whether that contraction is phasic or tonic
(i.e., rapid versus sustained contraction) [19]. Contraction is initiated by calcium-regulated
myosin light chain phosphorylation, involving calmodulin rather than the calcium-activated
troponin system (as in striated and cardiac muscle), and involves the sliding of actin-myosin
filaments [1].
3. Smooth muscle cells in disease
Structural and functional changes to smooth muscle cells and their microenvironment
contributes to tissue remodeling in diseases such as lung obstructive and vascular diseases
[2-5], which are the focus of this chapter. Tissue remodeling involving smooth muscle cells is
likely to be a result of injury and dys-regulated repair processes linked to inflammation and
extravascular coagulation and fibrinolysis [20-23].
3.1. Obstructive lung diseases
Obstructive lung diseases, including asthma, COPD, bronchitis and bronchiectasis, are
characterized by airway obstruction. The latter is a limitation of airflow, caused by the
narrowing of bronchioles. The mechano-contractile properties of the ASM cell make it the
primary effecter of bronchospasm, which is an acute contraction of the airways that occurs in
asthma and bronchitis. ASM cells are also involved in the array of persistent tissue structural
changes of the airway wall that contribute to airway obstruction in asthma and COPD [2, 24,
25]. In airway wall remodeling (AWR), ASM cell hyperplasia, hypertrophy and changes in
production of ECM protein contribute to an increase in airway wall thickness and reduction
in airway wall distensibility [26]. ASM cells in disease are major contributors to the increases
in production of ECM components, including the wound type collagens, I and III, and
fibronectin. ASM cells also have an important inflammatory role in airway obstructive
diseases, being potent producers of growth factors, cytokines and other pro-inflammatory
mediators, including granulocyte macrophage-colony stimulating factor (GM-CSF), intracel‐
lular adhesion molecule (ICAM), interleukin-1α (IL-1 α), eotaxin, leukaemia inhibitory (LIF),
fractalkine and vascular cell adhesion molecule (VCAM) [10]. Pro-inflammatory mediator
expression in ASM cells is stimulated primarily by cytokines and growth factors produced by
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inflammatory cells and the epithelium [27]. The ECM in the microenvironment of the ASM
cell can modulate cytokine expression by ASM cells [28]. Furthermore, cyclical changes in
mechanical strain associated with breathing also modulate cytokine expression by ASM cells
[29]. As a consequence of their pivotal role in AWR, therapies that target the ASM cell are
continually being explored as possible new treatments for obstructive lung diseases [30].
Although eliminating ASM by bronchial thermoplasty is effective in reducing airway obstruc‐
tion, less invasive and costly therapies are urgently needed. An effective muscle relaxing, anti-
remodeling treatment that specifically targets ASM cells is expected to reduce airway reactivity
and symptoms in patients with asthma or COPD [31, 32].
3.2. Vascular diseases
VSM cells reside in the medial layer of blood vessels, mediating changes in vascular tone by
contracting or relaxing in response to vasoconstrictors and vasodilators respectively. In
vascular injury and disease, VSM cells switch from a quiescent, contractile phenotype to a
synthetic phenotype, which produces cytokines and ECM protein (e.g., fibronectin and
sulphated proteoglycans), undergoes hyperplasia (i.e., increased proliferation) and/or hyper‐
trophy (i.e., increased cell size). In atherosclerosis, a cause of stenosis and blood vessel
occlusion, synthetic VSM cells migrate from the media to the intima where they proliferate
and contribute to intimal thickening [22, 23]. Furthermore, within the intima, VSM can alter
the composition of the ECM. For example, VSM cells produce increased amounts of LDL-
accumulating sulphated proteoglycans, which increase lipid loading, a feature of athero‐
thrombotic disease [33]. In hypertension, VSM cells undergo hypertrophic remodeling in the
media of blood vessels, contributing to excessive arterial vascular contractile tone, hence high
blood pressure [34]. Hypoxia, inflammation and shear stress contribute to vasoconstriction
and pulmonary vascular remodeling in PAH [35, 36]. Medial thickening in proximal pulmo‐
nary vessels is caused by the hypertrophy, hyperplasia and ECM production of resident VSM
cells, whereas in pre-capillary arterioles, the VSM cells that contribute to medial thickening
are derived from intermediate cells in blood vessels or adventitial fibroblasts, which differen‐
tiate into VSM. Like ASM cells, VSMs contribute to inflammation in vascular disease by
producing pro-inflammatory mediators such as the platelet-derived growth factor (PDGF),
transforming growth factor-β (TGF-β), interferon-γ (IFN- γ), and monocyte chemotactic
protein-1 (MCP-1). Furthermore, VSM cells express CAMs (e.g., VCAM-1 and ICAM-1), which
have a role in retaining monocytes and macrophages within lesions such as those formed in
the intima in atherosclerosis. Aberrant Akt/PI3kinase signaling resulting from a defect in PTEN
phosphatase activity is thought to contribute to the pro-inflammatory phenotype of VSM cells
in PAH [37]. In a murine model of PAH, the targeting of the PTEN gene specifically in VSM
cells augments an inflammatory response and vascular remodeling [38].
4. ECM of smooth muscle
The ECM of the smooth muscle cell microenvironment changes in injury, disease and with
ageing. ECM production and modification by smooth muscle cell is regulated by intrinsic
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(e.g., epigenetics) and extrinsic (e.g., oxidative stress, growth factors and cytokines) factors [15].
Abnormalities of the ECM are a key feature of tissue remodeling in obstructive lung [39] and
vascular disease [34].
4.1. Collagen
Collagen is the most prominent structural protein of connective tissue. Native collagen I and
III form fibrils comprising supra-molecular aggregates of collagen that are stabilized by
interactions between their helical domains [40]. These fibrils have a high tensile strength that
maintains the structural integrity of tissue by counter-balancing distending forces, such as
those evoked by breathing on the airway wall [41]. In the airways of patients with asthma and
COPD, the ECM is expanded by fibrils of collagen I and III, including around and within
smooth muscle bundles, reducing airway wall distensibility [26]. Increased collagen, as well
as ASM hyperplasia and hypertrophy, also contribute to airway wall thickening that is linked
to increased airway-reactivity [2]. In the media of the healthy blood vessel wall, collagen I and
III are the main components of the ECM, with elastin also being abundant in the media of
larger arterioles [42, 43]. Collagen fibrils formed by VSM cells also have an important role in
fibrous cap stabilization, a stage of atherogenesis [44]. Whilst the native forms of collagen
impose mechanical strain on cells, it is the denatured forms of collagen, which perhaps are
more biochemically-reactive. Increases in the activities of plasmin and MMPs, proteases which
denature native collagen, occur in both respiratory [45] and vascular [34] disease. The dena‐
turation of collagen fibrils immediately adjacent to and surrounding smooth muscle cells by
pericellular proteolysis may have an important role in regulating phenotype and function in
disease.
4.2. Fibronectin
Fibronectin is a high molecular weight glycoprotein and constituent of the ECM. Fibronectin
binds to the α5β1 integrin on cells to transmit biochemical and mechanical signals, and is a
nucleator of fibrillogenesis (i.e., collagen fibril assembly). In asthma, levels of fibronectin, along
with collagen I and III, are increased within the smooth muscle bundle of the airway wall [46].
Additionally, ASM cells from asthmatics, when compared to non-asthmatics, secrete more
fibronectin, which in turn augments increased ASM cell proliferation and cytokine production
[47]. Rhinovirus-infection [48], cigarette smoke extract [49] and the pro-fibrogenic mediator
TGF-β [50], all stimulate ASM cells to produce fibronectin. VSM cells in disease also produce
increased amounts of fibronectin. During atherogenesis, fibronectin synthesized by VSM cells
becomes more abundant in the blood vessel wall, which augments fibrillogenesis [44] and
stimulates smooth muscle cell proliferation and cytokine production [42, 43].
4.3. Fibrin
Extravascular accumulation of fibrin, formed by the coagulation cascade, occurs in a number
of diseases, including respiratory and vascular diseases [21, 51-55]. Increased vascular
permeability allows blood-circulating hemostatic factors such as factor VII (FVII), factor X (FX)
Smooth Muscle and Extracellular Matrix Interactions in Health and Disease
http://dx.doi.org/10.5772/60403
363
and plasminogen to enter damaged and inflamed tissue to become activated and participate
in coagulation and fibrinolysis (Figure 1).
Figure 1. Extravascular coagulation and fibrinolysis. In inflamed tissue such as the airway wall in asthma, plasma con‐
taining factor VII (FVII) and FX leak into the extravascular compartment. FVII, combined with tissue factor (TF),
formed by epithelial, stromal (e.g., smooth muscle cells) and inflammatory cells, transforms FX into the serine pro‐
tease, FXa. The latter, combined with FV, activates thrombin, which in turn converts fibrinogen into fibrin. Whilst fi‐
brin has an important role in physiological wound-repair, it also serves as a scaffold for migrating stromal cells, and
can be converted into fibrin degradation products (FDPs), which stimulate smooth muscle cell migration and cytokine
production. Fibrinolysis (i.e., the break-down of fibrin) is catalysed by plasmin, formed by the activation of plasma-
derived plasminogen. The latter is catalysed by tissue-type plasminogen activator (tPA).
Abundant extravascular fibrin is a specific hallmark of lung disease including asthma, and is
thought to be a result of hyper-coagulation and suppressed fibrinolysis (i.e., fibrin degrada‐
tion). The key mediator of fibrinolysis is plasmin, which can be formed by the proteolytic
activation of plasminogen by either the tissue-type or urokinase type plasminogen activators
(tPA or uPA respectively) [56, 57]. However, only tPA has fibrin-dependent amplification
activity, facilitating its role as the primary mediator of fibrinolysis. Levels of tPA are much
higher than uPA in the airway lumen [58-60]. The reduced AWR observed in plasminogen
activator inhibitor-1 (PAI-1) gene knockout mice challenged with aerosolized allergen is likely
to be a consequence of less airway fibrin [61, 62]. PAI-1 inhibits fibrinolysis by blocking the
actions tPA in plasmin formation.
The medial layer of blood vessels, where VSM cells are prominent in number, is exposed to
plasma exudate, even under normal physiological conditions. Whilst fibrin is present in
normal arterial intima, its levels are increased in atherosclerotic lesions, particularly early
proliferative, gelatinous-lesions [21]. Again, hypercoaulation and suppressed fibrinolysis are
likely to contribute to increased fibrin formation in the vasculature in disease. The coagulant,
tissue factor (TF), is highly expressed in VSM cells during atherogenesis [7], being rapidly
induced by growth factors and cytokines [7]. Hypoxia, a driver of PAH, induces the up-
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regulation of PAI-1 in pulmonary artery VSM cells [63]. In injury and disease, the deposition
of fibrin into the ECM serves as a scaffold to support smooth muscle cell migration [64].
Furthermore, fibrin degradation products (FDPs) formed by fibrinolysis, stimulate production
of pro-inflammatory mediators (e.g., C-reactive protein in VSM cells [65]).
4.4. Proteolglycans
Proteoglycans are another important component of the ECM synthesized by smooth muscle
cells in disease including VSM cells during atherogenesis [42, 43] and ASM cells in asthma [66].
In atherogenesis, sulphated proteoglycans, via ionic interactions with ApoB100 and ApoE,
entrap low-density lipoprotein (LDL) within the vessel wall. Bound oxidized-LDL augments
macrophage lipid uptake and foam cell formation, and stimulates VSM cells to secrete greater
amounts of sulphated proteoglycans [34].
5. ECM remodeling by smooth muscle cells
Asides from producing ECM protein, smooth muscle cells also modulate the structure and
form of the ECM. Extracellular modification of ECM protein involves integrins and enzymes
which proteolyze and cross-link collagen. The serine protease, plasmin, also has the ability to
directly activate smooth muscle cells via receptor based mechanisms. Major modifications of
ECM protein by smooth muscle cells are described below:
5.1. Fibrillogenesis
Smooth muscle cells including VSM [67] and ASM [68] cells polymerize collagen fibrils into
larger supramolecular collagen assemblies. Collagen fibrils can vary greatly in diameter
(20-500 nm) and form different supramolecular structures such as bundles, weaves, and layers
to suit differing roles and functions. The ability of smooth muscle cells to increase the diameter
of fibrils would increase the tensile strength and resistance of the fibrils to collagenolysis by
MMPs. Collagen fibrillogenesis involves integrin binding (e.g., α2β1, α11β1) and is integrated
with fibronectin fibril formation [69]. Lipid accumulation by VSM cells inhibits collagen
fibrillogenesis [70], contributing to the destabilization of fibrous caps, hence rupture of
atherosclerotic plaques [44].
5.2. Proteolysis
Matrix metalloproteases (MMPs) and plasmin are proteases involved in the degradation of
ECM proteins such as fibronectin and denatured collagen. Plasmin also cleaves and activates
the zymogen forms of MMPs including the MMP collagenases (MMP-1, MMP-13 and
MMP-14), which denature collagen fibrils [71]. MMPs including MMP-1, MMP-2, MMP-12 and
MMP-14 are expressed by human ASM cells in vivo [72] and/or in vitro [68] and conversion of
plasminogen into plasmin by ASM cells is associated with MMP activation and increases in
collageneolytic activity [73]. MMPs and components of the plasminogen activation system are
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co-expressed during remodeling in the airways following allergen challenge [74]. VSM cells
also produce and secrete MMPs including MMP-2, MMP-3, MMP-7 and MMP-9 [34]. MMPs
formed by VSM cells are considered to contribute to the thinning, thus destabilization of the
atherosclerotic fibrous cap in atherogenesis [44]. Like ASM cells, VSM cells do not produce
plasminogen de novo, but express urokinase plasminogen activator (uPA), which readily
activates plasminogen convected from plasma through the blood vessel wall [22]. Hypoxia
induces uPA expression in VSM cells, in association with increased cell migration and matrix
invasion, suggesting a role of plasmin proteolysis in PAH [8].
Interestingly uPA and plasminogen gene deletion (but not tPA gene deletion) also reduces
hypoxia-induced PAH and pulmonary vascular remodeling in mice [75]. These effects are
likely to be independent of fibrinolysis, as uPA does not bind fibrin with the same high affinity
as tPA. Plasmin formed by uPA has pro-inflammatory and -remodeling activities which are
not associated with the break-down of fibrin. Furthermore, uPA has plasmin(ogen)-independ‐
ent effects. The amino-terminal fragment of uPA interacts with its receptor, uPAR to activate
other receptors such as the formyl-peptide receptor 2 (FPR2) [76] and the epidermal growth
factor receptor (EGFR) [77], to regulate migration, chemotaxis and cytokine production. uPA
binding also regulates the affinity of uPAR for the α3β1-integrin [78], to regulate cell adhesion
and cell signaling. Furthermore, the kringle domain of uPA interacts with the αvβ1-integrin
in an uPAR-independent manner [79]. Increases in the levels of uPA are associated with a
number of pathologies, including asthma, COPD and PAH [59, 60, 80-82]. For smooth muscle
cells, plasminogen activation by uPA is accelerated by the annexin A2 hetero-tetramer (AIIt)
[83], an extracellular protein complex comprised of annexin A2 and S100A10 (p11). The AIIt
also serves as a signal transducer for plasmin in mediating its pro-inflammatory effects on
ASM cells [84] and macrophages [85]. The importance of annexin A2 in cancer is becoming
increasingly recognised, however, little is still known about the role of annexin A2 in respira‐
tory disease [86-90].
The proteolytic  activity of  plasmin releases the otherwise latent forms of growth factors
such  as  epidermal  growth  factor  (EGF)  and  TGF-β  [91,  92].  Plasminogen  activation  by
smooth  muscle  cells  is  associated  with  MMP  activation  [73]  and  targeting  the  EGF-
receptor (EGFR) or MMPs attenuates plasmin(ogen)-stimulated proliferation [83]. The effects
of plasmin(ogen) on EGFR signaling are contributed by heparan sulphate proteoglycan -
binding EGF (HB-EGF), an EGFR ligand, which is released from heparin by MMP-mediat‐
ed proteolysis  (Figure 2).  Like EGFR transactivation,  plasmin-stimulated mobilization of
matrix-bound TGF-β contributes to collagen synthesis in smooth muscle cells in a manner
involving TGF-β receptor signaling [91]. TGF-β also stimulates ASM cell proliferation [93],
in an indirect manner involving autocrine bFGF production [94].
Plasmin also activates the protease-activated receptor-1 (PAR-1), the proto-typical receptor of
thrombin (and FXa). PAR-1 is expressed in inflammatory cells including, macrophages, mast
cells and eosinophils [96-99], and extravascular structural cells including, smooth muscle cells
[100]. Activation of PAR-1 in stromal cells is considered to evoke pro-tissue remodeling
activities, which contributes to disease pathology. Levels of PARs are increased in structural
cells in tissue remodeling lung diseases [101], and targeting PAR-1 reduces pulmonary
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inflammation and tissue remodeling in mouse models of lung injury and disease, including
asthma [98, 102, 103]. Furthermore, PAR-1 activation elicits increased cytokine and collagen
expression [103-105] and proliferation [106] of lung stromal cells, including ASM cells [107].
The up-regulation of both PAR-1 and PAR-2 in VSM cells following injury and their subse‐
quent activation by hemostatic proteases is considered to contribute to the pathogenesis of
atherosclerosis [5]. Whilst plasmin has ~10 times less affinity for PAR-1 than thrombin [108],
integrin co-receptors augment plasmin-evoked PAR-1 activation [109]. Binding to α9β1 integrin
localizes plasmin to the cell surface and protects it from α2-antiplasmin inhibition, increasing
PAR-1 activation, whilst also activating pathways downstream of α9β1 integrin through
integrin-linked kinase (ILK) [109]. Additionally to plasmin, the plasmin-activated MMP-1 and
MMP-13 also cleave the N-terminal exodomain of PAR-1, but at sites alternative to those of
thrombin, FXa and plasmin, eliciting distinct cellular responses [110].
5.3. Cross-linking
Dysregulated matrix cross-linking and stability contributes to tissue remodeling in vascular
disease and ageing. Lysyl oxidases cross-link collagen fibrils by modification of the ε-amino
group in the side chain of lysines. Lysyl oxidase activity is increased in the vascular lesions of
patients with PAH [9]. The expression of lysyl oxidases in VSM cells is responsive to hypoxia
and increases in the lungs of mice in experimental PAH [9]. Glycation of collagens also induces
covalent bridges between collagen fibrils, an age-related modification that contributes to
arterial stiffness [34]. Similarly, vascular calcification, which involves transglutaminase-2-
induced collagen crosslinking and dimerization of osteopontin, is a degenerative and end-
stage process of atherosclerosis, which also contributes to the stiffness of ageing arteries [111].
Vascular calcification involves the de-differentiation of the VSM cell to a pro-calcificatory
phenotype, where expression of the matrix Gla protein (MGP) and bone morphogenetic
protein-2 (BMP-2) are decreased and increased respectively.
Figure 2. Plasmin-evoked EGFR transactivation. HB-EGF is an important ligand of EGFR, and is released from hepar‐
an sulphate proteoglycan by the proteolytic actions of MMPs. HB-EGF is expressed in the airway epithelium and
smooth muscle in situ [95].
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6. Smooth muscle cell and ECM interactions
Smooth muscle cells  are highly sensitive to the biochemical  and mechanical  state of  the
surrounding ECM. Signal transduction, and the transmission and distribution of mechani‐
cal forces within the cell are dependent on the actin-cytoskeleton. This deformable polymer
network also has important roles in maintaining cell shape (size) and cell migration [112].
The  interaction  of  the  actin-cytoskeleton  with  the  contractile  apparatus  and  the  ECM
involves  integrins  and focal  adhesion  (FA)  complexes,  and is  a  key  determinant  of  the
biochemical  and mechano-sensing properties of  smooth muscle cells.  The highly mallea‐
ble actin-cytoskeleton constantly rearranges, in a process involving assembly and disassem‐
bly,  in  response to  both bio-physical  and -chemical  stimuli  [113].  Alterations  in  smooth
muscle stiffness in health and disease involve changes to actin-cytoskeleton organization,
which is influenced by the ECM [114].
6.1. Biochemical transduction
Biochemically, ECM protein signal through integrin receptors and the dystrophin-glycopro‐
tein complex in smooth muscle cells [115]. The native fibrillar and denatured non-fibrillar
forms of collagen regulate smooth muscle cell function differentially. The anti-proliferative
effect of fibrillar collagen type I on VSM [116] and ASM [68] cells, which arrest cells in the G1
phase of the cell cycle, involves α2β1 integrin binding. Although, the non-fibrillar forms of
collagen types I and III do not contribute structurally to tissue integrity, they retain cell
signaling activity. The GFOGER motif of the characteristic triple helix of non-fibrillar type I
collagen binds with high affinity to the integrins α1β1, α2β1, α10β1, and α11β1 [117]. Fur‐
thermore, proteolytic cleavage of the helix by MMPs and plasmin reveals the ‘matricryptic’
RGD integrin-binding site [118]. Non-fibrillar type I collagen stimulates smooth muscle cell
proliferation [119], survival [120], and cytokine release [28] in an integrin-dependent manner.
Similarly, fibronectin, which binds α5β1 integrin via its RGD motif, also stimulates smooth
muscle cell proliferation [119] and augments cytokine production in response to stimuli such
as IL-1β [28]. Fibrin degradation products (FDPs) also regulate smooth muscle cell migration
via binding the α5β3 integrin [64], as well as stimulating smooth muscle cell cytokine produc‐
tion and proliferation via binding TLR-4 [121].
6.2. Mechano-transduction
Connections between the ECM and the actin cytoskeleton of smooth muscle cells allows for
an efficient transfer of force between the contractile apparatus and the extracellular environ‐
ment, which is important in myogenic force generation [122]. These same connections, which
involve integrins and FA complexes, also regulate smooth muscle cell stiffness and phenotype.
Mechanical forces, whether external or internal to tissue in which smooth muscle cells reside,
stretch and strain protein-cell surface integrin FA complexes, activating downstream intracel‐
lular signaling pathways. This process is termed mechano-transduction, and often elicits
mechanically sensitive ion channels to open or close, changing the polarity of the membrane
potential, which then activates voltage-gated channels. Mechanical strain in smooth muscle
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cells activates RhoA, a pivotal regulator of actin adhesion organization [123]. The β1-integrin
is an important mechanoreceptor, regulating cell function and viability via the inositol 3-kinase
(PI3K)/Akt signaling pathway, in a process involving FA kinase (FAK) and integrin-linked
kinase (ILK) phosphorylation [124, 125].
In arterial blood vessels, integrin-mediated mechano-transduction triggers intracellular Ca2+
mobilization in VSM cells to evoke myogenic responses [126]. The integrin-mediated adhesion
of VSM cells to the ECM is dynamically regulated in opposing directions by vasoconstrictors
(e.g., angiotensin II) and vasodilators (e.g., nitric oxide) to control cell contractility, hence blood
vessel tone [127]. VSM cells are in turn subject to varying mechanical strain (i.e., intraluminal
pressure) generated by moving blood. In the airways, the ASM cell regulates bronchomotor
tone, contracting in response to various contractile agonists including acetylcholine, serotonin,
histamine and endothelin-1 [128]. The ASM cell is also subject to mechanical forces resulting
from cyclical expansion of airway diameter and cyclical lengthening of the airway wall due to
breathing [122]. The ECM modulates the effects of these forces on cell function and phenotype.
Cyclical strain (4% elongation) that is equivalent to normal breathing inhibits ASM cell
proliferation when grown on laminin, but not collagen type I (denatured) in vitro [129]. The
ratio of laminin to collagen is higher in the airways of non-asthmatics than asthmatics. When
ASM cells grown on type I collagen are subject to increased cyclical strain (17-18% elongation),
equivalent to those generated by bronchospasm and hyperinflation, an increase in migration
and proliferation occurs in a MMP-dependent manner [130].
In disease, smooth muscle cell biology is affected by changes in the ECM, including increases
in substrate stiffness and the generation of isometric forces in tethered collagen lattices, which
influence mechano-transduction. In severe asthma, the “strait jacket” effect of ASM cells being
embedded in a rigid microenvironment may reduce the amplitude of the oscillatory forces
associated with breathing. This is likely to have potential consequences on smooth muscle
biology, as has been proposed for lung fibroblasts in fibrotic foci (FF) lesions in idiopathic
pulmonary fibrosis (IPF) [131]. Tensile collagen fibrils within FF form a rigid environment that
reduces the magnitude of cyclical strain the fibroblasts are normally subjected to in healthy
tissue upon breathing. A reduction in the amplitude of force of breathing-associated cyclical
strain is thought to increase lung fibroblast fibrogenic activity and stiffness.
6.3. Interconnection of biochemical- and mechanical-evoked signaling
ECM biochemistry and mechanics are very much interconnected in their regulation of smooth
muscle behavior. The influence of mechanics on smooth muscle cell biology is modulated by
ligand biochemistry. For example, smooth muscle cells grown on fibronectin, as compared to
laminin, exhibit increased cell adhesion and cytoskeletal polymerization in response to
increasing stiffness of the substrata, i.e., the ‘stiffness by ligand’ effect [132]. In VSM cells, FAs
formed by cell contact with different ECM proteins, exhibit different mechanical characteristics
resulting in distinct force-generating reactions [133]. VSM cells attach more strongly to
fibronectin than collagen type I, vitronectin and laminin, to evoke greater myogenic force-
generation [133]. Integrin co-receptors may also modulate PAR-1 and uPA signaling in
response to biomechanical forces. uPA elicits cellular responses via binding its receptor, uPAR,
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which lacks a transmembrane or intracellular domain [78]. The interaction of uPA with uPAR
to activate co-receptors including integrins, is likely to be influenced by the engagement of
integrins with the ECM. In support, fibulin 5 [127] and vitronectin [41] are integrin binding
ECM proteins, which modulate uPA-uPAR signaling [134]. uPAR-independent activation of
αvβ1-integrin by uPA in smooth muscle cell may also be similarly affected by the ECM and
biomechanical forces [79].
7. Targeting smooth muscle cell biology as therapy
Strategies that target smooth muscle cell biology, including ECM-smooth muscle cell interac‐
tions, may be beneficial in the treatment of tissue remodeling diseases. Approaches that target
proteases, which modulate the ECM or ECM-signaling of smooth muscle cells in disease, will
be of particular focus in this chapter section.
7.1. Contractile, hypertrophic and hyperplasic regulators
Targeting factors which regulate smooth muscle contractility, hyperplasia and/or hypertrophy
are currently used in the treatment of airway and vascular diseases. β2-Adrenergic receptor
agonists, which increase the intracellular second messenger, cyclic AMP (cAMP), in ASM cells,
are used pharmacologically to dampen bronchoconstriction in asthma and COPD [135].
Blockade of endothelin (ET) receptors are an effective treatment for PAH. Endothelin-1 (ET-1)
is both a vasoconstrictor and mitogen, evoking its effects on VSM cells through binding to
ETA or ETB receptors. Another treatment of PAH is prostacyclin (or its analogs), an eicosanoid,
which like the prostaglandins and thromboxane, is vasodilatory [136]. Eicosanoids, which are
released by endothelial cells, stimulate increases in the levels of intracellular cAMP in VSM
cells via binding prostanoid/G-protein coupled receptors. Increases in cAMP inhibit myosin
light chain phosphorylation, causing relaxation, as well as inhibiting proliferation [137].
Similarly, the endogenous vasodilator nitric oxide (NO), which is released by endothelial cells,
also inhibits both myosin light chain phosphorylation (via increases in cGMP) and proliferation
of VSM cells [36]. Various NO donors such as glycerine trinitrate and sodium nitroprusside
(SNP) have been used in the treatment of vascular disease and endothelial dysfunction (e.g.,
angina pectoris and hypertension) [138].
7.2. Growth factors
Growth factors such as PDGF, TGF-β and VEGF which regulate smooth muscle proliferation
and size, may also be potential targets for the treatment of vascular and lung obstructive
diseases [15]. Imatinib, a receptor tyrosine kinase inhibitor which inhibits PDGF signaling,
attenuates both VSM cell hyperplasia and hypertrophy in pre-clinical models of vascular
disease [139]. However, imatinib was withdrawn from clinical trials for the treatment of
advanced PAH, because of serious side effects and increased morbidity [140]. Inhibiting
specific aspects of TGF-β signaling may be another growth factor-targeting strategy to treat
tissue remodeling in disease. Aberrant TGF-β signaling, important in regulating smooth
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muscle function including cell stiffness and proliferation [141, 142], contributes to tissue
remodeling in vascular and respiratory diseases [143-145]. The TGF-β superfamily member,
activin A, is linked with the progression of PAH, stimulating VSM cell proliferation [141].
Administration of follistatin, an endogenous inhibitor of activin A, attenuates inflammation
and remodeling in experimental models of lung injury and disease [146].
7.3. MMPs
Targeting  proteases  that  modify  smooth  muscle  ECM  structure  and  its  biomechanical
properties are another strategy to treat vascular and obstructive lung disease. Inhibition of
pericellular collagenolysis in situ may reduce ASM cell hyperplasia in AWR by maintain‐
ing the anti-proliferative effects of fibrillar pericellular collagen. Administration of the MMP
inhibitory  antibiotic  doxycycline  reduces  airway  hyper-responsiveness  in  allergen-chal‐
lenged mice [147],  supporting the concept that interventions with selective MMP inhibi‐
tors could be beneficial in the treatment of diseases such as asthma (see Table 1). In pre-
clinical  models of vascular disease and injury,  doxycycline has been shown to attenuate
acute  pulmonary  thromboembolism  (APT)-evoked  pulmonary  hypertension  and  right
ventricular dysfunction [148].
The effects of targeting ECM proteases in experimental models of lung and vascular disease
Target Approach Model (challenge) Outcome (as compared to wild type or
vehicle control treated mice following
challenge or injury)
Annexin A2 Genetic
(annexin A2 knockout)
Allergen Reduced airway inflammation [84].
FXa Pharmacological
(Fondaparinux)
Allergen Reduced AWR. Administered after AWR
was established [149].
Lysyl oxidase Pharmacological
(β-aminopropionitrile)
Arterial injury Reduced perturbations to right ventricular
systolic pressure, right ventricular
hypertrophy, and vessel muscularization
and normalized collagen cross-linking and
vessel matrix architecture
MMPs Pharmacological
(doxycycline)
Allergen Reduced airway hyper-responsiveness
[147].
MMPs Pharmacological
(doxycycline)
APT Reduced hypertension and right
ventricular dysfunction [148].
Plasminogen Pharmacological Allergen Reduced eosinophil and lymphocyte
numbers, mucus production, and collagen
deposition in the lungs [74].
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The effects of targeting ECM proteases in experimental models of lung and vascular disease
Target Approach Model (challenge) Outcome (as compared to wild type or
vehicle control treated mice following
challenge or injury)
(tranexamic acid) and genetic
(plasminogen knockout)
Plasminogen Genetic
(plasminogen knockout)
Bleomycin Reduced alveolar macrophage / Increased
lung collagen [150].
Plasminogen Genetic
(plasminogen knockout)
Hypoxia Reduced pulmonary hypertension and
pulmonary vascular remodeling [75].
Plasminogen Genetic
(plasminogen knockout)
Hypoxia No effect [75].
PAI-1 Pharmacological (IMD-1622) Arterial injury Reduced arterial neointimal formation,
increases in adhesion molecules, fibrinogen
accumulation [151]
PAI-1 Genetic (PAI-1 knockout) Allergen Reduced AWR including sub-epithelial
fibrosis [61, 62].
PAI-1 Genetic (PAI-1 knockout) Bleomycin Reduced lung collagen [152].
PAI-1 Pharmacological (Tiplaxtinin) Allergen Reduced AWR [153]
PAI-1 Genetic (PAI-1 knockout) Endotoxin Reduced neutrophil recruitment to the
lungs [154] and fibrin deposition and AWR
in the airways [155].
PAI-1 Genetic (PAI-1 knockout) Arterial injury Reduced arterial neointimal formation
[156].
PAR-1 Pharmacological
(ER-112780-06)
Allergen Reduced AWR [98].
PAR-1 Genetic (PAR-1 knockout) Bleomycin Reduced collagen accumulation in lung
and pulmnonary inflammation [102].
PAR-1 Pharmacological (Atopaxar) APT Reduced neointimal thickening in arterial
blood vessels [157]
PAR-1 Pharmacological (F16618) Balloon angioplasty Reduced restenosis [158]
tPA Therapeutic (nebulized tPA) Allergen Reduced airway hyper-responsiveness [52]
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The effects of targeting ECM proteases in experimental models of lung and vascular disease
Target Approach Model (challenge) Outcome (as compared to wild type or
vehicle control treated mice following
challenge or injury)
tPA Genetic (tPA knockout) Bleomycin Increased lung collagen/ alveolar
hemorrhage [150].
tPA Genetic (tPA knockout) Hypoxia Had no effect on pulmonary hypertension
or pulmonary vascular remodeling [75].
uPA Therapeutic (anti-uPA
antibodies)
Endotoxin Reduced inflammation and edema [159]
uPA Genetic (uPA knockout) Bleomycin Reduced alveolar macrophages [150].
uPA Genetic (uPA knockout) Endotoxin Reduced lung edema, pulmonary
neutrophil accumulation, and pro-
inflammatory cytokine levels [160].
uPA Genetic (uPA knockout) Hypoxia Reduced pulmonary hypertension and
pulmonary vascular remodeling [75].
uPAR Genetic (uPAR knockout) Bleomycin Reduced alveolar macrophages [150].
Table 1. A summary of findings from studies that have targeted ECM proteases and receptors in experimental models
of lung and vascular disease. The animal models used were: (i) Acute pulmonary thromboembolism (APT), Which is
induced with autologous blood clots; (ii) Allergen, A model of allergic airway inflammation which has characteristics
of asthma pathology. In the model, antigen sensitized animals are repeatedly challenged with aerosolized antigen (e.g.,
ovalbumin, house dust mite extract); (iii) Balloon angioplasty, A vascular intervention procedure which causes
restenosis; (iv) Bleomycin, Intranasal administration of bleomycin induces acute lung injury and subsequent
pulmonary inflammation and fibrosis. This model also features extensive remodeling in the upper airways involving
ASM cell hypertrophy and hyperplasia; (v) Endotoxin, Intranasal administration of endotoxin (i.e., lipopolysaccharide
or LPS) also induces acute lung injury and pulmonary inflammation; and (vi) Hypoxia, A model of pulmonary arterial
hypertension (PAH).
7.4. Coagulants
Reducing the accumulation of extravascular fibrin in damaged tissue would be expected to
reduce tissue remodeling in disease. Anti-coagulants are already used in the treatment of
vascular disease to reduce thrombosis by disrupting hemostasis. Whilst clinical asthma trials
with nebulized heparin have provided mixed results [161], systemic administration of
fondaparinux, a selective inhibitor of FXa, attenuates AWR in experimental asthma [149] (table
1). The success of anticoagulant therapy in treating asthma and other respiratory diseases may
depend on the anticoagulant, which differ in potency for coagulation-dependent and -
independent targets. Selective small molecule FXa inhibitors (e.g., apixaban) are used as
treatment for venous thromboembolism and stroke prevention in patients with atrial fibrilla‐
tion [162], but still have anti-coagulant related bleeding risks, which can be potentially fatal.
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The coagulants FXa and thrombin may also contribute to tissue remodeling via their activation
of PAR-1 on stromal cells including ASM and VSM cells. PAR-1 antagonists reduce AWR in a
murine model of chronic allergic airway inflammation [98] and pulmonary inflammation and
fibrosis in mice following bleomycin-induced lung injury [102, 103] (table 1). Similarly PAR-1
antagonists reduce restenosis [158] and intimal thickening [157] in the vascular wall following
balloon injury in vivo (table 1). Orally administered Vorapaxar, a PAR-1 inhibitor, is used as
anti-platelet therapy for prevention of secondary thrombotic cardiovascular events in patients
with a prior myocardial infarction [163]. However, it is because of the ability to suppress
thrombin-stimulated platelet aggregation, thus disrupting hemostasis, that PAR-1 inhibitors
such as Vorapaxar are associated with potentially fatal bleeding complications [164]. For PAR-1
inhibitors to be used as treatment for tissue remodeling disease, they will need to be modified
to selectively target the extravascular cell-mediated actions of coagulant proteases without
disrupting hemostasis. Taking advantage of integrin co-receptors and adaptors that differen‐
tiate PAR-1 responses in platelet and endothelial cells as compared to inflammatory and
extravascular structural cells (e.g. smooth muscle cells) may be one approach to achieve
selectively in regards to PAR-1-drug targeting.
7.5. Fibrinolytic agents
Potential therapies that reduce fibrin by using fibrinolytic agents, have been considered in the
treatment of lung disease for some time [165]. Thrombolytic therapy using tPA-mimetics are
already used for stroke and myocardial infarction, despite a higher risk of bleeding compli‐
cations [166]. A potential strategy to treat asthma is to augment airspace fibrinolysis. Tiplax‐
tinin, a small molecule inhibitor of PAI-1 [153], or inhaled tPA [52], attenuate AWR or reactivity
in allergen-challenged mice (table 1). In animal studies of vascular injury and disease, PAI-1
inhibitors [151] or PAI-1 gene deletion [156] reduced neointima formation.
7.6. uPA and annexin A2
Both uPA and annexin A2 may be potential novel drug targets in the treatment of chronic
respiratory disease [167]. Both uPA and annexin A2 gene-deletion reduces pulmonary
inflammation in various murine models [84, 150, 160], and uPA antibodies reduce inflamma‐
tion and edema in a mouse model of acute lung injury [159] (table 1). However, further pre-
clinical characterization of these inhibitors as therapy for tissue remodeling diseases is
required. The roles of uPA and annexin A2 in cancer are well established, and their targeting
by either pharmacological or antibody-based therapies have been shown to reduce tumour
growth and/or metastasis in a number of pre-clinical cancer models [86-90]. Furthermore,
clinical trials for cancer have shown uPA inhibitors are well tolerated in humans and have
generated promising results [87].
7.7. Cross-linking enzymes
As the expression of lysyl oxidases are dysregulated in PAH, modulation of lung matrix cross-
linking may limit pulmonary vascular remodeling associated with PAH. In support, β-
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aminopropionitrile, an inhibitor of lysyl oxidase, attenuates the effect of hypoxia on vascular
remodeling in experimental PAH [9] (table 1).
7.8. Actin-cytoskeleton
Cytoskeletal changes in smooth muscle cells occur in association with increases in stiffness
(i.e., elastic modulus), size (hypertrophy) and migration [168-170]. A strategy that softens cells
by regulating the formation or depolymerisation of the actin-cytoskeleton may be beneficial
in the treatment of vascular and lung obstructive diseases. However, there are yet no actin-
targeting drugs used clinically [171]. Cytochalasins and latrunculins are cytotoxic as they non-
selectively disrupt actin microfilaments. However, there are different populations of actin
filaments, spatially organised into distinct cellular compartments with unique functions. Their
organization is regulated by associated-actin binding proteins. Therapeutically, actin filament
populations need to be targeted specifically, by modulating the binding of specific actin-
binding proteins. One approach maybe to target the assembly of FA complexes. Phosphory‐
lation of FAK leads to disassembly of FA complexes-actin filaments [172]. ECM proteins
(e.g., collagen and fibronectin) that engage integrins regulate FAK activity and actin-cytoske‐
leton organization [173]. FAK regulates actin-cytoskeleton organisation by modulating the
association of actin with actin-capping proteins such as gelsolin [174]. Complexes between
FAK, gelsolin and the actin-cytoskeleton also regulate gene expression of contractile proteins
(e.g., α-smooth muscle actin, calponin and transgelin [SM22]) via the actin-filament-dependent
transcriptional co-activator, MRTF-A (myocardin-related transcription factor-A) [174].
8. Conclusion
Understanding the molecular mechanisms by which the ECM regulates smooth muscle cell
function in disease remains a key challenge to developing effective therapeutics for managing
tissue remodeling diseases such as obstructive lung and vascular diseases. Insight into the
biology of the smooth muscle cell in these diseases has increased rapidly in the recent years,
leading to the concept that successful strategies for managing tissue remodeling may include
restoring smooth muscle phenotype. Such approaches could possibly involve modulating the
ECM of the smooth muscle microenvironment, or the factors which are involved in the
transmission of the biochemical and biomechanical properties of the ECM. Proteases of the
coagulation and plasminogen activation systems are of particular interest as therapeutic
targets, as they not only have roles in forming and modifying ECM, but also can directly
stimulate changes in smooth muscle cell function and phenotype. The challenge is to target
these proteases without disrupting their roles in hemostasis, in order to avoid bleeding
complications.
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